Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED SCHEDULE OF INVESTMENTS

v3.22.4
CONSOLIDATED SCHEDULE OF INVESTMENTS
£ in Thousands, $ in Thousands
Dec. 31, 2022
USD ($)
shares
Dec. 31, 2022
GBP (£)
shares
Dec. 31, 2021
USD ($)
shares
Dec. 31, 2021
GBP (£)
shares
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate 7.50% 7.50%    
Investment cost $ 3,005,696   $ 2,390,984  
Total investments at fair value 2,963,955   2,434,522  
Investment Funds & Vehicles [Member]        
Investment Holdings [Line Items]        
Investment cost [1]     2,032  
Total investments at fair value 3,893   1,814  
Senior Secured Debt        
Investment Holdings [Line Items]        
Total investments at fair value 2,741,388   2,156,709  
Unsecured        
Investment Holdings [Line Items]        
Total investments at fair value 54,056   52,890  
Debt Investments        
Investment Holdings [Line Items]        
Investment cost 2,818,060 [2]   2,219,586 [1]  
Total investments at fair value 2,795,444   2,209,599  
Equity        
Investment Holdings [Line Items]        
Investment cost 153,173 [2]   142,219  
Total investments at fair value 133,972   184,710  
Equity | Preferred Stock        
Investment Holdings [Line Items]        
Total investments at fair value 41,488   69,439  
Equity | Common Stock        
Investment Holdings [Line Items]        
Total investments at fair value 92,484   115,271  
Warrant Investment        
Investment Holdings [Line Items]        
Investment cost 30,964 [2]   27,147 [1]  
Total investments at fair value 30,646   38,399  
Investments in Securities        
Investment Holdings [Line Items]        
Investment cost 3,002,197 [2]   2,388,952 [1]  
Total investments at fair value 2,960,062   2,432,708  
Investment        
Investment Holdings [Line Items]        
Investment cost 3,005,696 [2]   2,390,984 [1]  
Total investments at fair value 2,963,955   2,434,522  
Forbion Growth Opportunities Fund I C V | Investment Funds & Vehicles [Member]        
Investment Holdings [Line Items]        
Investment cost [1],[3],[4],[5]     2,032  
Total investments at fair value [3],[4],[5]     $ 1,814  
Acquisition Date [6]     Nov. 16, 2020 Nov. 16, 2020
Black Crow AI, Inc. affiliates        
Investment Holdings [Line Items]        
Principal Amount     $ 3,000  
Medrobotics Corporation [Member] | Warrant Investment | Preferred Series E        
Investment Holdings [Line Items]        
Acquisition Date [6]     Mar. 13, 2013 Mar. 13, 2013
Biotechnology Tools        
Investment Holdings [Line Items]        
Total investments at fair value 32,825   $ 0  
Biotechnology Tools | Debt Investments        
Investment Holdings [Line Items]        
Investment cost [2] 32,339      
Total investments at fair value 32,339      
Biotechnology Tools | Warrant Investment        
Investment Holdings [Line Items]        
Investment cost [2] 485      
Total investments at fair value $ 486      
Biotechnology Tools | Alamar Biosciences, Inc. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2026-06 2026-06    
Investment Interest Rate Floor [7] 6.50% 6.50%    
Investment Interest Rate Paid in Kind [7] 1.00% 1.00%    
Principal Amount [8] $ 5,000      
Investment cost [2],[8] 4,951      
Total investments at fair value [8] $ 4,951      
Biotechnology Tools | Alamar Biosciences, Inc. | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 5.95% 5.95%    
Biotechnology Tools | Alamar Biosciences, Inc. | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 3.00% 3.00%    
Biotechnology Tools | Alamar Biosciences, Inc. | Warrant Investment | Preferred Series B        
Investment Holdings [Line Items]        
Investment cost [2] $ 24      
Total investments at fair value $ 23      
Acquisition Date [9] Jun. 21, 2022 Jun. 21, 2022    
Shares | shares 15,399 15,399    
Biotechnology Tools | PathAI, Inc | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2027-01 2027-01    
Investment Interest Rate Floor [7] 9.15% 9.15%    
Principal Amount [8] $ 28,000      
Investment cost [2],[8] 27,388      
Total investments at fair value [8] $ 27,388      
Biotechnology Tools | PathAI, Inc | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 11.21% 11.21%    
Biotechnology Tools | PathAI, Inc | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 2.15% 2.15%    
Biotechnology Tools | PathAI, Inc | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2] $ 461      
Total investments at fair value $ 463      
Acquisition Date [9] Dec. 23, 2022 Dec. 23, 2022    
Shares | shares 53,418 53,418    
Communications & Networking        
Investment Holdings [Line Items]        
Total investments at fair value $ 101,833   105,490  
Communications & Networking | Debt Investments        
Investment Holdings [Line Items]        
Investment cost 99,167 [2]   97,088 [1]  
Total investments at fair value 101,734   99,230  
Communications & Networking | Equity        
Investment Holdings [Line Items]        
Investment cost [1]     1,230  
Total investments at fair value     6,260  
Communications & Networking | Warrant Investment        
Investment Holdings [Line Items]        
Investment cost 541 [2]   418  
Total investments at fair value $ 99   $ 0  
Communications & Networking | Aryaka Networks, Inc. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2026-07 2026-07    
Investment Interest Rate Floor [7] 6.75% 6.75%    
Investment Interest Rate Paid in Kind [7] 1.05% 1.05%    
Principal Amount [8],[10],[11] $ 5,023      
Investment cost [2],[8],[10],[11] 4,969      
Total investments at fair value [8],[10],[11] $ 5,053      
Communications & Networking | Aryaka Networks, Inc. | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 3.55% 3.55%    
Communications & Networking | Aryaka Networks, Inc. | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 3.25% 3.25%    
Communications & Networking | Aryaka Networks, Inc. | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2] $ 123      
Total investments at fair value $ 99      
Acquisition Date [9] Jun. 28, 2022 Jun. 28, 2022    
Shares | shares 229,611 229,611    
Communications & Networking | Cytracom Holdings LLC | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2025-02 2025-02 2025-02 2025-02
Investment Interest Rate Floor 10.31% [7] 10.31% [7] 10.31% [12] 10.31% [12]
Principal Amount $ 8,910 [8],[13],[14]   $ 9,000 [3],[15],[16]  
Investment cost 8,768 [2],[8],[13],[14]   8,802 [1],[3],[15],[16]  
Total investments at fair value $ 8,748 [8],[13],[14]   $ 8,725 [3],[15],[16]  
Communications & Networking | Cytracom Holdings LLC | Senior Secured Debt | LIBOR        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate 9.31% [7] 9.31% [7] 9.31% [12] 9.31% [12]
Communications & Networking | Spring Mobile Solutions, Inc. | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 418 [2]   $ 418  
Total investments at fair value   $ 0  
Acquisition Date Apr. 19, 2013 [9] Apr. 19, 2013 [9] Apr. 19, 2013 [6] Apr. 19, 2013 [6]
Shares | shares 2,834,375 2,834,375 2,834,375 2,834,375
Communications & Networking | Rocket Lab Global Services, LLC | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2024-06 2024-06 2024-06 2024-06
Investment Interest Rate Floor 8.15% [7] 8.15% [7] 8.15% [12] 8.15% [12]
Investment Interest Rate Paid in Kind 1.25% [7] 1.25% [7] 1.25% [12] 1.25% [12]
Principal Amount $ 84,581 [11],[13],[17],[18],[19]   $ 88,542 [20],[21]  
Investment cost 85,430 [2],[11],[13],[17],[18],[19]   88,286 [1],[20],[21]  
Total investments at fair value $ 87,933 [11],[13],[17],[18],[19]   $ 90,505 [20],[21]  
Communications & Networking | Rocket Lab Global Services, LLC | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor 3.25% [7] 3.25% [7] 3.25% [12] 3.25% [12]
Communications & Networking | Rocket Lab Global Services, LLC | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate 4.90% [7] 4.90% [7] 4.90% [12] 4.90% [12]
Communications & Networking | Peerless Network Holdings, Inc. | Equity        
Investment Holdings [Line Items]        
Investment cost [1]     $ 1,230  
Total investments at fair value     $ 6,260  
Shares | shares     1,138,328 1,138,328
Communications & Networking | Peerless Network Holdings, Inc. | Equity | Preferred Series A        
Investment Holdings [Line Items]        
Investment cost [1]     $ 1,230  
Total investments at fair value     $ 6,242  
Acquisition Date [6]     Apr. 11, 2008 Apr. 11, 2008
Shares | shares     1,135,000 1,135,000
Communications & Networking | Peerless Network Holdings, Inc. | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost [1]     $ 0  
Total investments at fair value     $ 18  
Acquisition Date [6]     Oct. 21, 2020 Oct. 21, 2020
Shares | shares     3,328 3,328
Consumer & Business Products        
Investment Holdings [Line Items]        
Total investments at fair value $ 2,821   $ 28,099  
Consumer & Business Products | Debt Investments        
Investment Holdings [Line Items]        
Investment cost [1]     23,162  
Total investments at fair value     23,298  
Consumer & Business Products | Equity        
Investment Holdings [Line Items]        
Investment cost 663 [2]   128 [1]  
Total investments at fair value 498   447  
Consumer & Business Products | Warrant Investment        
Investment Holdings [Line Items]        
Investment cost 1,712 [2]   2,145 [1]  
Total investments at fair value 2,323   4,354  
Consumer & Business Products | TechStyle, Inc. | Warrant Investment | Preferred Series B        
Investment Holdings [Line Items]        
Investment cost [2] 1,101      
Total investments at fair value $ 745      
Acquisition Date [9] Jul. 16, 2013 Jul. 16, 2013    
Shares | shares 206,185 206,185    
Consumer & Business Products | Whoop, Inc. | Warrant Investment | Preferred Series C        
Investment Holdings [Line Items]        
Investment cost $ 18 [2]   18 [1]  
Total investments at fair value $ 475   $ 1,847  
Acquisition Date Jun. 27, 2018 [9] Jun. 27, 2018 [9] Jun. 27, 2018 [6] Jun. 27, 2018 [6]
Shares | shares 686,270 686,270 686,270 686,270
Consumer & Business Products | The Neat Company | Common Stock | Preferred Series C        
Investment Holdings [Line Items]        
Total investments at fair value     $ 0  
Consumer & Business Products | The Neat Company | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 365 [2]   $ 365 [1]  
Total investments at fair value      
Acquisition Date Aug. 13, 2014 [9] Aug. 13, 2014 [9] Aug. 13, 2014 [6] Aug. 13, 2014 [6]
Shares | shares 54,054 54,054 54,054 54,054
Consumer & Business Products | Grove Collaborative, Inc. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date     2025-04 2025-04
Investment Interest Rate Floor [12]     8.75% 8.75%
Principal Amount [22]     $ 23,520  
Investment cost [1],[22]     23,162  
Total investments at fair value [22]     $ 23,298  
Consumer & Business Products | Grove Collaborative, Inc. | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [12]     6.75% 6.75%
Consumer & Business Products | Grove Collaborative, Inc. | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [12]     5.50% 5.50%
Consumer & Business Products | Grove Collaborative, Inc. | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2],[9] $ 433      
Total investments at fair value [9] $ 24      
Acquisition Date [9] Apr. 30, 2021 Apr. 30, 2021    
Shares | shares [9] 61,300 61,300    
Consumer & Business Products | Grove Collaborative, Inc. | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost [1]     $ 433  
Total investments at fair value     $ 326  
Acquisition Date [6]     Apr. 30, 2021 Apr. 30, 2021
Shares | shares     83,625 83,625
Consumer & Business Products | Penumbra Brands, LLC (p.k.a. Gadget Guard) | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost [1]     $ 228  
Total investments at fair value     $ 0  
Acquisition Date [6]     Jun. 03, 2014 Jun. 03, 2014
Shares | shares     1,662,441 1,662,441
Consumer & Business Products | TFG Holding, Inc. | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2] $ 89      
Total investments at fair value $ 116      
Acquisition Date [9] Apr. 30, 2010 Apr. 30, 2010    
Shares | shares 42,989 42,989    
Consumer & Business Products | TFG Holding, Inc. | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2] $ 0      
Total investments at fair value      
Acquisition Date [9] Jun. 27, 2014 Jun. 27, 2014    
Shares | shares 206,185 206,185    
Consumer & Business Products | Savage X Holding, LLC | Equity | Class A Units        
Investment Holdings [Line Items]        
Investment cost [2] $ 13      
Total investments at fair value $ 226      
Acquisition Date [9] Apr. 30, 2010 Apr. 30, 2010    
Shares | shares 42,137 42,137    
Consumer & Business Products | Savage X Holding, LLC | Warrant Investment | Class A Units        
Investment Holdings [Line Items]        
Investment cost [2] $ 0      
Total investments at fair value $ 1,103      
Acquisition Date [9] Jun. 27, 2014 Jun. 27, 2014    
Shares | shares 206,185 206,185    
Consumer & Business Products | TechStyle, Inc. (p.k.a. Just Fabulous, Inc.) | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 128 [2]   $ 128 [1]  
Total investments at fair value $ 132   $ 447  
Acquisition Date Apr. 30, 2010 [9] Apr. 30, 2010 [9] Apr. 30, 2010 [6] Apr. 30, 2010 [6]
Shares | shares 42,989 42,989 42,989 42,989
Consumer & Business Products | TechStyle, Inc. (p.k.a. Just Fabulous, Inc.) | Warrant Investment | Preferred Series B        
Investment Holdings [Line Items]        
Investment cost [1]     $ 1,101  
Total investments at fair value     $ 2,181  
Acquisition Date [6]     Jul. 16, 2013 Jul. 16, 2013
Shares | shares     206,185 206,185
Consumer & Business Products | Gadget Guard, LLC | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2] $ 228      
Total investments at fair value      
Acquisition Date [9] Jun. 03, 2014 Jun. 03, 2014    
Shares | shares 1,662,441 1,662,441    
Consumer & Business Services | Debt Investments        
Investment Holdings [Line Items]        
Investment cost [2] $ 444,703      
Total investments at fair value 428,750      
Consumer & Business Services | Equity        
Investment Holdings [Line Items]        
Investment cost [2] 13,488      
Total investments at fair value 7,995      
Consumer & Business Services | Warrant Investment        
Investment Holdings [Line Items]        
Investment cost [2] 4,248      
Total investments at fair value $ 2,639      
Consumer & Business Services | Jobandtalent USA, Inc. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2025-02 2025-02    
Investment Interest Rate Floor [7] 9.75% 9.75%    
Principal Amount [23],[24] $ 14,000      
Investment cost [2],[23],[24] 13,853      
Total investments at fair value [23],[24] $ 13,904      
Consumer & Business Services | Jobandtalent USA, Inc. | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 3.00% 3.00%    
Consumer & Business Services | Jobandtalent USA, Inc. | Senior Secured Debt | SOFR        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 8.86% 8.86%    
Consumer & Business Services | Provi | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2026-12 2026-12    
Investment Interest Rate Floor [7] 10.65% 10.65%    
Principal Amount [25] $ 15,000      
Investment cost [2],[25] 14,739      
Total investments at fair value [25] $ 14,739      
Consumer & Business Services | Provi | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 2.95% 2.95%    
Consumer & Business Services | Provi | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 4.40% 4.40%    
Consumer & Business Services | Provi | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2],[25] $ 166      
Total investments at fair value [25] $ 155      
Acquisition Date [9] Dec. 22, 2022 Dec. 22, 2022    
Shares | shares [25] 117,042 117,042    
Consumer & Business Services | Veem, Inc. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2025-03 2025-03    
Investment Interest Rate Floor [7] 7.25% 7.25%    
Investment Interest Rate Paid in Kind [7] 1.25% 1.25%    
Principal Amount [11],[17] $ 5,043      
Investment cost [2],[11],[17] 5,000      
Total investments at fair value [11],[17] $ 5,042      
Consumer & Business Services | Veem, Inc. | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 4.50% 4.50%    
Consumer & Business Services | Veem, Inc. | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 4.00% 4.00%    
Consumer & Business Services | Veem, Inc. | Debt Investments        
Investment Holdings [Line Items]        
Principal Amount $ 10,076      
Investment cost [2] 9,988      
Total investments at fair value 10,166      
Consumer & Business Services | Veem, Inc. | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2] 126      
Total investments at fair value $ 25      
Acquisition Date [9] Mar. 31, 2022 Mar. 31, 2022    
Shares | shares 98,428 98,428    
Consumer & Business Services | Veem, Inc. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2025-03 2025-03    
Investment Interest Rate Floor [7] 7.95% 7.95%    
Investment Interest Rate Paid in Kind [7] 1.50% 1.50%    
Principal Amount [11] $ 5,033      
Investment cost [2],[11] 4,988      
Total investments at fair value [11] $ 5,124      
Consumer & Business Services | Veem, Inc. | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 4.50% 4.50%    
Consumer & Business Services | Veem, Inc. | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 4.70% 4.70%    
Consumer & Business Services | RVShare, LLC | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2026-12 2026-12    
Investment Interest Rate Floor [7] 6.50% 6.50%    
Investment Interest Rate Paid in Kind [7] 4.00% 4.00%    
Principal Amount [8],[11],[17],[25] $ 27,730      
Investment cost [2],[8],[11],[17],[25] 27,265      
Total investments at fair value [8],[11],[17],[25] $ 27,256      
Consumer & Business Services | RVShare, LLC | Senior Secured Debt | LIBOR        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 5.50% 5.50%    
Consumer & Business Services | Snagajobcom Inc | Warrant Investment        
Investment Holdings [Line Items]        
Investment cost [2] $ 860      
Total investments at fair value $ 118      
Shares | shares 3,611,537 3,611,537    
Consumer & Business Services | Snagajobcom Inc | Warrant Investment | Preferred Series A        
Investment Holdings [Line Items]        
Investment cost [2] $ 782      
Total investments at fair value $ 50      
Acquisition Date [9] Jun. 30, 2016 Jun. 30, 2016    
Shares | shares 1,800,000 1,800,000    
Consumer & Business Services | Snagajobcom Inc | Warrant Investment | Preferred Series B        
Investment Holdings [Line Items]        
Investment cost [2] $ 62      
Total investments at fair value $ 25      
Acquisition Date [9] Aug. 01, 2018 Aug. 01, 2018    
Shares | shares 1,211,537 1,211,537    
Consumer & Business Services | Snagajobcom Inc | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2] $ 16      
Total investments at fair value $ 43      
Acquisition Date [9] Apr. 20, 2020 Apr. 20, 2020    
Shares | shares 600,000 600,000    
Consumer & Business Services | RumbleON, Inc. | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2],[9] $ 88      
Total investments at fair value [9] $ 0      
Acquisition Date [9] Apr. 30, 2018 Apr. 30, 2018    
Shares | shares [9] 5,139 5,139    
Consumer & Business Services | Lendio, Inc. | Warrant Investment | Preferred Series D        
Investment Holdings [Line Items]        
Investment cost [2] $ 39      
Total investments at fair value $ 19      
Acquisition Date [9] Mar. 29, 2019 Mar. 29, 2019    
Shares | shares 127,032 127,032    
Consumer & Business Services | Landing Holdings Inc. | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2],[25] $ 116      
Total investments at fair value [25] $ 127      
Acquisition Date [9] Mar. 12, 2021 Mar. 12, 2021    
Shares | shares [25] 11,806 11,806    
Consumer & Business Services | Lyft Inc | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2],[9] $ 5,263      
Total investments at fair value [9] $ 1,110      
Acquisition Date [9] Dec. 26, 2018 Dec. 26, 2018    
Shares | shares [9] 100,738 100,738    
Consumer & Business Services | Uber Technologies, Inc. | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2],[9] $ 318      
Total investments at fair value [9] $ 816      
Acquisition Date [9] Dec. 01, 2020 Dec. 01, 2020    
Shares | shares [9] 32,991 32,991    
Consumer & Business Services | Nerdy Inc. | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2],[9] $ 1,000      
Total investments at fair value [9] $ 225      
Acquisition Date [9] Sep. 17, 2021 Sep. 17, 2021    
Shares | shares [9] 100,000 100,000    
Consumer & Business Services | DoorDash, Inc. | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2],[9] $ 945      
Total investments at fair value [9] $ 4,003      
Acquisition Date [9] Dec. 20, 2018 Dec. 20, 2018    
Shares | shares [9] 81,996 81,996    
Consumer & Business Services | OfferUp, Inc. | Equity        
Investment Holdings [Line Items]        
Investment cost [2] $ 2,295      
Total investments at fair value $ 513      
Shares | shares 394,790 394,790    
Consumer & Business Services | OfferUp, Inc. | Equity | Preferred Series A        
Investment Holdings [Line Items]        
Investment cost [2] $ 1,663      
Total investments at fair value $ 372      
Acquisition Date [9] Oct. 25, 2016 Oct. 25, 2016    
Shares | shares 286,080 286,080    
Consumer & Business Services | OfferUp, Inc. | Equity | Preferred Series A-1        
Investment Holdings [Line Items]        
Investment cost [2] $ 632      
Total investments at fair value $ 141      
Acquisition Date [9] Oct. 25, 2016 Oct. 25, 2016    
Shares | shares 108,710 108,710    
Consumer & Business Services | Oportun | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2],[9] $ 577      
Total investments at fair value [9] $ 266      
Acquisition Date [9] Jun. 28, 2013 Jun. 28, 2013    
Shares | shares [9] 48,365 48,365    
Consumer & Business Services | Reischling Press, Inc. | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2] $ 39      
Total investments at fair value      
Acquisition Date [9] Jul. 31, 2020 Jul. 31, 2020    
Shares | shares 3,095 3,095    
Consumer & Business Services | App Direct Incorporation | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2026-04 2026-04    
Investment Interest Rate Floor [7] 8.75% 8.75%    
Principal Amount [8],[18] $ 40,790      
Investment cost [2],[8],[18] 41,856      
Total investments at fair value [8],[18] $ 42,426      
Consumer & Business Services | App Direct Incorporation | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 8.29% 8.29%    
Consumer & Business Services | App Direct Incorporation | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 5.50% 5.50%    
Consumer & Business Services | Carwow LTD | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2024-12 2024-12    
Investment Interest Rate Floor [7] 7.95% 7.95%    
Investment Interest Rate Paid in Kind [7] 1.45% 1.45%    
Principal Amount | £ [11],[23],[24]   £ 18,890    
Investment cost [2],[11],[23],[24] $ 26,024      
Total investments at fair value [11],[23],[24] $ 22,971      
Consumer & Business Services | Carwow LTD | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 4.95% 4.95%    
Consumer & Business Services | Carwow LTD | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 4.70% 4.70%    
Consumer & Business Services | Carwow LTD | Equity | Preferred Series D-4        
Investment Holdings [Line Items]        
Investment cost [2],[23],[24] $ 1,151      
Total investments at fair value [23],[24] $ 257      
Acquisition Date [9] Dec. 15, 2021 Dec. 15, 2021    
Shares | shares [23],[24] 199,742 199,742    
Consumer & Business Services | Carwow LTD | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2],[23],[24] $ 164      
Total investments at fair value [23],[24] $ 34      
Acquisition Date [9] Dec. 14, 2021 Dec. 14, 2021    
Shares | shares [23],[24] 174,163 174,163    
Consumer & Business Services | Houzz, Inc. | Convertible Debt        
Investment Holdings [Line Items]        
Maturity Date 2028-05 2028-05    
Investment Interest Rate Paid in Kind [7] 5.50% 5.50%    
Principal Amount [11],[26] $ 21,853      
Investment cost [2],[11],[26] 21,853      
Total investments at fair value [11],[26] 20,356      
Consumer & Business Services | Houzz, Inc. | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2] 20      
Total investments at fair value      
Acquisition Date [9] Oct. 29, 2019 Oct. 29, 2019    
Shares | shares 529,661 529,661    
Consumer & Business Services | Rhino Labs Incorporation | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2024-03 2024-03    
Investment Interest Rate Floor [7] 8.75% 8.75%    
Investment Interest Rate Paid in Kind [7] 2.25% 2.25%    
Principal Amount [11],[25] $ 16,500      
Investment cost [2],[11],[25] 16,328      
Total investments at fair value [11],[25] $ 16,496      
Consumer & Business Services | Rhino Labs Incorporation | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 5.50% 5.50%    
Consumer & Business Services | Rhino Labs Incorporation | Equity | Preferred Series B-2        
Investment Holdings [Line Items]        
Investment cost [2] $ 1,000      
Total investments at fair value $ 805      
Acquisition Date [9] Jan. 24, 2022 Jan. 24, 2022    
Shares | shares 7,063 7,063    
Consumer & Business Services | Rhino Labs Incorporation | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2],[25] $ 470      
Total investments at fair value [25] $ 308      
Acquisition Date [9] Mar. 12, 2021 Mar. 12, 2021    
Shares | shares [25] 13,106 13,106    
Consumer & Business Services | SeatGeek, Inc. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2023-06 2023-06    
Investment Interest Rate Floor [7] 10.50% 10.50%    
Investment Interest Rate Paid in Kind [7] 0.50% 0.50%    
Principal Amount [11],[17],[18],[19] $ 60,915      
Investment cost [2],[11],[17],[18],[19] 60,721      
Total investments at fair value [11],[17],[18],[19] $ 60,721      
Consumer & Business Services | SeatGeek, Inc. | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 5.00% 5.00%    
Consumer & Business Services | SeatGeek, Inc. | Debt Investments        
Investment Holdings [Line Items]        
Principal Amount $ 85,986      
Investment cost [2] 85,633      
Total investments at fair value 86,544      
Consumer & Business Services | SeatGeek, Inc. | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2],[18],[19] 842      
Total investments at fair value [18],[19] $ 1,332      
Acquisition Date [9] Jun. 12, 2019 Jun. 12, 2019    
Shares | shares [18],[19] 1,379,761 1,379,761    
Consumer & Business Services | SeatGeek, Inc. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2026-05 2026-05    
Investment Interest Rate Floor [7] 10.50% 10.50%    
Investment Interest Rate Paid in Kind [7] 0.50% 0.50%    
Principal Amount [11],[13],[19] $ 25,071      
Investment cost [2],[11],[13],[19] 24,912      
Total investments at fair value [11],[13],[19] $ 25,823      
Consumer & Business Services | SeatGeek, Inc. | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 7.00% 7.00%    
Consumer & Business Services | Skyword, Inc. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2026-11 2026-11    
Investment Interest Rate Floor [7] 9.25% 9.25%    
Investment Interest Rate Paid in Kind [7] 1.75% 1.75%    
Principal Amount [11],[17] $ 9,007      
Investment cost [2],[11],[17] 8,918      
Total investments at fair value [11],[17] $ 8,870      
Consumer & Business Services | Skyword, Inc. | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 3.00% 3.00%    
Consumer & Business Services | Skyword, Inc. | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 2.75% 2.75%    
Consumer & Business Services | Skyword, Inc. | Warrant Investment        
Investment Holdings [Line Items]        
Investment cost [2] $ 140      
Total investments at fair value $ 43      
Shares | shares 2,051,587 2,051,587    
Consumer & Business Services | Skyword, Inc. | Warrant Investment | Preferred Series B        
Investment Holdings [Line Items]        
Investment cost [2] $ 83      
Total investments at fair value      
Acquisition Date [9] Aug. 23, 2019 Aug. 23, 2019    
Shares | shares 444,444 444,444    
Consumer & Business Services | Skyword, Inc. | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2] $ 57      
Total investments at fair value $ 43      
Acquisition Date [9] Nov. 14, 2022 Nov. 14, 2022    
Shares | shares 1,607,143 1,607,143    
Consumer & Business Services | Tectura Corporation | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2024-07 2024-07    
Investment Interest Rate Paid in Kind [7] 5.00% 5.00%    
Principal Amount [11],[27],[28] $ 10,680      
Investment cost [2],[11],[27],[28] 240      
Total investments at fair value [11],[27],[28] 0      
Consumer & Business Services | Tectura Corporation | Debt Investments        
Investment Holdings [Line Items]        
Principal Amount 31,953      
Investment cost [2] 21,513      
Total investments at fair value $ 8,042      
Consumer & Business Services | Tectura Corporation | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2024-07 2024-07    
Principal Amount [11],[27],[28] $ 8,250      
Investment Interest Rate Paid in Cash [7] 8.25% 8.25%    
Investment cost [2],[11],[27],[28] $ 8,250      
Total investments at fair value [11],[27],[28] $ 8,042      
Consumer & Business Services | Tectura Corporation | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2024-07 2024-07    
Investment Interest Rate Paid in Kind [7] 5.00% 5.00%    
Principal Amount [11],[27],[28] $ 13,023      
Investment cost [2],[11],[27],[28] 13,023      
Total investments at fair value [11],[27],[28] 0      
Consumer & Business Services | Tectura Corporation | Equity        
Investment Holdings [Line Items]        
Investment cost [2] 900      
Total investments at fair value      
Shares | shares 415,994,863 415,994,863    
Consumer & Business Services | Tectura Corporation | Equity | Preferred Series BB        
Investment Holdings [Line Items]        
Investment cost [27] $ 0      
Total investments at fair value [27] $ 0      
Acquisition Date [9] Jun. 06, 2016 Jun. 06, 2016    
Shares | shares [27] 1,000,000 1,000,000    
Consumer & Business Services | Tectura Corporation | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2],[27] $ 900      
Total investments at fair value [27] $ 0      
Acquisition Date [9] May 23, 2018 May 23, 2018    
Shares | shares [27] 414,994,863 414,994,863    
Consumer & Business Services | Thumbtack, Inc. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2026-04 2026-04    
Investment Interest Rate Floor [7] 8.20% 8.20%    
Investment Interest Rate Paid in Kind [7] 1.50% 1.50%    
Principal Amount [8],[11],[18] $ 10,103      
Investment cost [2],[8],[11],[18] 10,050      
Total investments at fair value [8],[11],[18] $ 10,167      
Consumer & Business Services | Thumbtack, Inc. | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 3.95% 3.95%    
Consumer & Business Services | Thumbtack, Inc. | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 4.95% 4.95%    
Consumer & Business Services | Thumbtack, Inc. | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2],[18] $ 844      
Total investments at fair value [18] $ 280      
Acquisition Date [9] May 01, 2018 May 01, 2018    
Shares | shares [18] 267,225 267,225    
Consumer & Business Services | Worldremit Group Limited | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2025-02 2025-02    
Investment Interest Rate Floor [7] 10.25% 10.25%    
Principal Amount [10],[13],[18],[19],[23],[24] $ 94,500      
Investment cost [2],[10],[13],[18],[19],[23],[24] 94,418      
Total investments at fair value [10],[13],[18],[19],[23],[24] $ 93,837      
Consumer & Business Services | Worldremit Group Limited | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 3.00% 3.00%    
Consumer & Business Services | Worldremit Group Limited | Senior Secured Debt | LIBOR        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 9.25% 9.25%    
Consumer & Business Services | Worldremit Group Limited | Warrant Investment        
Investment Holdings [Line Items]        
Investment cost [2] $ 155      
Total investments at fair value $ 194      
Shares | shares 79,083 79,083    
Consumer & Business Services | Worldremit Group Limited | Warrant Investment | Preferred Series D        
Investment Holdings [Line Items]        
Investment cost [2],[18],[19],[23],[24] $ 129      
Total investments at fair value [18],[19],[23],[24] $ 192      
Acquisition Date [9] Feb. 11, 2021 Feb. 11, 2021    
Shares | shares [18],[19],[23],[24] 77,215 77,215    
Consumer & Business Services | Worldremit Group Limited | Warrant Investment | Preferred Series E        
Investment Holdings [Line Items]        
Investment cost [2],[19],[23],[24] $ 26      
Total investments at fair value [19],[23],[24] $ 2      
Acquisition Date [9] Aug. 27, 2021 Aug. 27, 2021    
Shares | shares [19],[23],[24] 1,868 1,868    
Consumer & Business Services | Udacity, Inc. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2024-09 2024-09    
Investment Interest Rate Floor [7] 7.75% 7.75%    
Investment Interest Rate Paid in Kind [7] 2.00% 2.00%    
Principal Amount [11],[18] $ 51,937      
Investment cost [2],[11],[18] 52,265      
Total investments at fair value [11],[18] $ 52,976      
Consumer & Business Services | Udacity, Inc. | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 3.00% 3.00%    
Consumer & Business Services | Udacity, Inc. | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 4.50% 4.50%    
Consumer & Business Services | Udacity, Inc. | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2],[18] $ 218      
Total investments at fair value [18] $ 4      
Acquisition Date [9] Sep. 25, 2020 Sep. 25, 2020    
Shares | shares [18] 486,359 486,359    
Diversified Financial Services        
Investment Holdings [Line Items]        
Total investments at fair value $ 68,569   $ 65,073  
Diversified Financial Services | Debt Investments        
Investment Holdings [Line Items]        
Investment cost 36,567 [2]   33,738 [1]  
Total investments at fair value 33,700   32,465  
Diversified Financial Services | Equity        
Investment Holdings [Line Items]        
Investment cost 28,444 [2]   28,041 [1]  
Total investments at fair value $ 34,869   $ 32,608  
Diversified Financial Services | Gibraltar Business Capital, LLC | Unsecured        
Investment Holdings [Line Items]        
Maturity Date 2026-09 2026-09 2026-09 2026-09
Principal Amount $ 15,000 [27]   $ 15,000 [29]  
Investment Interest Rate Paid in Cash 14.50% [7] 14.50% [7] 14.50% [12] 14.50% [12]
Investment cost $ 14,715 [2],[27]   $ 14,662 [1],[29]  
Total investments at fair value 12,802 [27]   13,818 [29]  
Diversified Financial Services | Gibraltar Business Capital, LLC | Debt Investments        
Investment Holdings [Line Items]        
Principal Amount 25,000   25,000  
Investment cost 24,567 [2]   24,485 [1]  
Total investments at fair value 21,700   23,212  
Diversified Financial Services | Gibraltar Business Capital, LLC | Equity        
Investment Holdings [Line Items]        
Investment cost 28,006 [2]   28,006 [1]  
Total investments at fair value $ 15,244   $ 20,618  
Shares | shares 11,432,752 11,432,752 11,432,752 11,432,752
Diversified Financial Services | Gibraltar Business Capital, LLC | Equity | Preferred Series A        
Investment Holdings [Line Items]        
Investment cost [2],[27] $ 26,122      
Total investments at fair value [27] $ 14,137      
Acquisition Date [9] Mar. 01, 2018 Mar. 01, 2018    
Shares | shares [27] 10,602,752 10,602,752    
Diversified Financial Services | Gibraltar Business Capital, LLC | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 1,884 [2],[27]   $ 1,884 [1],[29]  
Total investments at fair value $ 1,107 [27]   $ 1,225 [29]  
Acquisition Date Mar. 01, 2018 [9] Mar. 01, 2018 [9] Mar. 01, 2018 [6] Mar. 01, 2018 [6]
Shares | shares 830,000 [27] 830,000 [27] 830,000 [29] 830,000 [29]
Diversified Financial Services | Gibraltar Business Capital L L C One | Unsecured        
Investment Holdings [Line Items]        
Maturity Date 2026-09 2026-09 2026-09 2026-09
Principal Amount $ 10,000 [27]   $ 10,000 [29]  
Investment Interest Rate Paid in Cash 11.50% [7] 11.50% [7] 11.50% [12] 11.50% [12]
Investment cost $ 9,852 [2],[27]   $ 9,823 [1],[29]  
Total investments at fair value $ 8,898 [27]   9,394 [29]  
Diversified Financial Services | Gibraltar Business Capital L L C One | Equity | Preferred Series A        
Investment Holdings [Line Items]        
Investment cost [1],[29]     26,122  
Total investments at fair value [29]     $ 19,393  
Acquisition Date [6]     Mar. 01, 2018 Mar. 01, 2018
Shares | shares [29]     10,602,752 10,602,752
Diversified Financial Services | Hercules Adviser LLC | Unsecured        
Investment Holdings [Line Items]        
Maturity Date 2025-06 2025-06 2023-05 2023-05
Principal Amount $ 12,000 [27]   $ 8,850 [29]  
Investment Interest Rate Paid in Cash 5.00% [7] 5.00% [7] 5.00% [12] 5.00% [12]
Investment cost $ 12,000 [2],[27]   $ 8,850 [1],[29]  
Total investments at fair value 12,000 [27]   8,850 [29]  
Diversified Financial Services | Hercules Adviser LLC | Equity | Member Units        
Investment Holdings [Line Items]        
Investment cost 35 [2],[27]   35 [1],[29]  
Total investments at fair value $ 19,153 [27]   $ 11,990 [29]  
Acquisition Date Mar. 26, 2021 [9] Mar. 26, 2021 [9] Mar. 26, 2021 [6] Mar. 26, 2021 [6]
Shares | shares 1 [27] 1 [27] 1 [29] 1 [29]
Diversified Financial Services | Newfront Insurance Holdings, Inc. | Convertible Debt        
Investment Holdings [Line Items]        
Maturity Date     2022-08 2022-08
Investment Interest Rate Floor [12]     0.19% 0.19%
Investment Interest Rate Paid in Kind [12]     0.19% 0.19%
Principal Amount [30]     $ 403  
Investment cost [1],[30]     403  
Total investments at fair value [30]     403  
Diversified Financial Services | Newfront Insurance Holdings, Inc. | Equity | Preferred Series D-2        
Investment Holdings [Line Items]        
Investment cost [2] $ 403      
Total investments at fair value $ 472      
Acquisition Date [9] Sep. 30, 2021 Sep. 30, 2021    
Shares | shares 210,282 210,282    
Drug Delivery        
Investment Holdings [Line Items]        
Total investments at fair value $ 90   368  
Drug Delivery | Equity        
Investment Holdings [Line Items]        
Investment cost 3,638 [2]   3,638 [1]  
Total investments at fair value 89   305  
Drug Delivery | Warrant Investment        
Investment Holdings [Line Items]        
Investment cost 465 [2]   465 [1]  
Total investments at fair value 1   63  
Drug Delivery | PDS Biotechnology Corporation | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2],[9] 390      
Total investments at fair value [9] $ 1      
Acquisition Date [9] Aug. 28, 2014 Aug. 28, 2014    
Shares | shares [9] 3,929 3,929    
Drug Delivery | Aerami Therapeutics Holdings, Inc. | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 74 [2]   74 [1]  
Total investments at fair value   $ 0  
Acquisition Date Sep. 30, 2015 [9] Sep. 30, 2015 [9] Sep. 30, 2015 [6] Sep. 30, 2015 [6]
Shares | shares 110,882 110,882 110,882 110,882
Drug Delivery | PDS Biotechnology Corporation (p.k.a. Edge Therapeutics, Inc.) | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 309 [2],[9]   $ 309 [1],[6]  
Total investments at fair value $ 33 [9]   $ 20 [6]  
Acquisition Date Apr. 06, 2015 [9] Apr. 06, 2015 [9] Apr. 06, 2015 [6] Apr. 06, 2015 [6]
Shares | shares 2,498 [9] 2,498 [9] 2,498 [6] 2,498 [6]
Drug Delivery | PDS Biotechnology Corporation (p.k.a. Edge Therapeutics, Inc.) | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost [1],[6]     $ 390  
Total investments at fair value [6]     $ 1  
Acquisition Date [6]     Aug. 28, 2014 Aug. 28, 2014
Shares | shares [6]     3,929 3,929
Drug Delivery | BioQ Pharma Incorporated | Equity | Preferred Series D        
Investment Holdings [Line Items]        
Investment cost $ 500 [2]   $ 500 [1]  
Total investments at fair value $ 33   $ 168  
Acquisition Date Dec. 08, 2015 [9] Dec. 08, 2015 [9] Dec. 08, 2015 [6] Dec. 08, 2015 [6]
Shares | shares 165,000 165,000 165,000 165,000
Drug Delivery | BioQ Pharma Incorporated | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 1 [2]   $ 1 [1]  
Total investments at fair value   $ 62  
Acquisition Date Oct. 27, 2014 [9] Oct. 27, 2014 [9] Oct. 27, 2014 [6] Oct. 27, 2014 [6]
Shares | shares 459,183 459,183 459,183 459,183
Drug Delivery | Aytu BioScience, Inc. (p.k.a. Neos Therapeutics, Inc.) | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 1,500 [2],[9]   $ 1,500 [1],[6]  
Total investments at fair value $ 3 [9]   $ 18 [6]  
Acquisition Date Mar. 28, 2014 [9] Mar. 28, 2014 [9] Mar. 28, 2014 [6] Mar. 28, 2014 [6]
Shares | shares 13,600 [9] 13,600 [9] 13,600 [6] 13,600 [6]
Drug Delivery | AcelRx Pharmaceuticals, Inc. | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 1,329 [2],[9]   $ 1,329 [1],[6]  
Total investments at fair value $ 20 [9]   $ 99 [6]  
Acquisition Date Dec. 10, 2018 [9] Dec. 10, 2018 [9] Dec. 10, 2018 [6] Dec. 10, 2018 [6]
Shares | shares 8,836 [9] 8,836 [9] 176,730 [6] 176,730 [6]
Drug Discovery & Development        
Investment Holdings [Line Items]        
Total investments at fair value $ 1,150,707   $ 967,383  
Drug Discovery & Development | Investment Funds & Vehicles [Member]        
Investment Holdings [Line Items]        
Investment cost [2] 3,118      
Total investments at fair value 3,518      
Drug Discovery & Development | Debt Investments        
Investment Holdings [Line Items]        
Investment cost 1,107,352 [2]   936,457 [1]  
Total investments at fair value 1,101,430   935,964  
Drug Discovery & Development | Equity        
Investment Holdings [Line Items]        
Investment cost 43,971 [2]   33,401 [1]  
Total investments at fair value 37,315   24,860  
Drug Discovery & Development | Warrant Investment        
Investment Holdings [Line Items]        
Investment cost 7,466 [2]   7,393 [1]  
Total investments at fair value 8,444   4,745  
Drug Discovery & Development | Forbion Growth Opportunities Fund I I C V | Investment Funds & Vehicles [Member]        
Investment Holdings [Line Items]        
Investment cost [2],[8],[23],[24] 419      
Total investments at fair value [8],[23],[24] $ 438      
Acquisition Date [9] Jun. 23, 2022 Jun. 23, 2022    
Drug Discovery & Development | Kineta, Inc. | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2],[9] $ 110      
Total investments at fair value [9] $ 0      
Acquisition Date [9] Dec. 20, 2019 Dec. 20, 2019    
Shares | shares [9] 2,202 2,202    
Drug Discovery & Development | Akero Therapeutics, Inc. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2027-01 2027-01    
Investment Interest Rate Floor [7] 7.65% 7.65%    
Principal Amount [8],[17],[23] $ 5,000      
Investment cost [2],[8],[17],[23] 4,986      
Total investments at fair value [8],[17],[23] $ 5,039      
Drug Discovery & Development | Akero Therapeutics, Inc. | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 5.85% 5.85%    
Drug Discovery & Development | Akero Therapeutics, Inc. | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 3.65% 3.65%    
Drug Discovery & Development | Akero Therapeutics, Inc. | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2],[9],[23] $ 1,000      
Total investments at fair value [9],[23] $ 2,108      
Acquisition Date [9] Sep. 19, 2022 Sep. 19, 2022    
Shares | shares [9],[23] 38,461 38,461    
Drug Discovery & Development | Akero Therapeutics, Inc. | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2],[9],[23] $ 56      
Total investments at fair value [9],[23] $ 674      
Acquisition Date [9] Jun. 15, 2022 Jun. 15, 2022    
Shares | shares [9],[23] 18,360 18,360    
Drug Discovery & Development | Alladapt Immunotherapeutics Inc | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2026-09 2026-09    
Investment Interest Rate Floor [7] 8.40% 8.40%    
Principal Amount [8],[17] $ 15,000      
Investment cost [2],[8],[17] 14,920      
Total investments at fair value [8],[17] $ 14,920      
Drug Discovery & Development | Alladapt Immunotherapeutics Inc | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 10.60% 10.60%    
Drug Discovery & Development | Alladapt Immunotherapeutics Inc | Senior Secured Debt | Cap rate        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 10.90% 10.90%    
Drug Discovery & Development | Alladapt Immunotherapeutics Inc | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 3.65% 3.65%    
Drug Discovery & Development | ATAI Life Sciences N.V. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2026-08 2026-08    
Investment Interest Rate Floor [7] 8.55% 8.55%    
Principal Amount [23],[24] $ 10,500      
Investment cost [2],[23],[24] 10,513      
Total investments at fair value [23],[24] $ 10,513      
Drug Discovery & Development | ATAI Life Sciences N.V. | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 6.95% 6.95%    
Drug Discovery & Development | ATAI Life Sciences N.V. | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 4.55% 4.55%    
Drug Discovery & Development | Provention Bio, Inc. [Member] | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2027-09 2027-09    
Investment Interest Rate Floor [7] 8.20% 8.20%    
Principal Amount [8] $ 25,000      
Investment cost [2],[8] 24,670      
Total investments at fair value [8] $ 24,670      
Drug Discovery & Development | Provention Bio, Inc. [Member] | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 6.60% 6.60%    
Drug Discovery & Development | Provention Bio, Inc. [Member] | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 2.70% 2.70%    
Drug Discovery & Development | Provention Bio, Inc. [Member] | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2],[9] $ 281      
Total investments at fair value [9] $ 677      
Acquisition Date [9] Sep. 15, 2022 Sep. 15, 2022    
Shares | shares [9] 111,934 111,934    
Drug Discovery & Development | Redshift Bioanalytics, Inc. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2026-01 2026-01    
Investment Interest Rate Floor [7] 7.50% 7.50%    
Principal Amount [25] $ 5,000      
Investment cost [2],[25] 4,957      
Total investments at fair value [25] $ 4,946      
Drug Discovery & Development | Redshift Bioanalytics, Inc. | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 3.80% 3.80%    
Drug Discovery & Development | Redshift Bioanalytics, Inc. | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 4.25% 4.25%    
Drug Discovery & Development | Redshift Bioanalytics, Inc. | Warrant Investment | Preferred Series E        
Investment Holdings [Line Items]        
Investment cost [2],[25] $ 20      
Total investments at fair value [25] $ 21      
Acquisition Date [9] Mar. 23, 2022 Mar. 23, 2022    
Shares | shares [25] 475,510 475,510    
Drug Discovery & Development | Replimune Group, Inc. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2027-10 2027-10    
Investment Interest Rate Floor [7] 7.25% 7.25%    
Investment Interest Rate Paid in Kind [7] 1.50% 1.50%    
Principal Amount [8],[11],[23] $ 20,754      
Investment cost [2],[8],[11],[23] 20,656      
Total investments at fair value [8],[11],[23] $ 20,656      
Drug Discovery & Development | Replimune Group, Inc. | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 4.95% 4.95%    
Drug Discovery & Development | Replimune Group, Inc. | Senior Secured Debt | Cap rate        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 9.00% 9.00%    
Drug Discovery & Development | Replimune Group, Inc. | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 1.75% 1.75%    
Drug Discovery & Development | Tarsus Pharmaceuticals, Inc. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2027-02 2027-02    
Investment Interest Rate Floor [7] 8.45% 8.45%    
Principal Amount [8],[17],[23] $ 8,250      
Investment cost [2],[8],[17],[23] 8,274      
Total investments at fair value [8],[17],[23] $ 8,423      
Drug Discovery & Development | Tarsus Pharmaceuticals, Inc. | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 4.75% 4.75%    
Drug Discovery & Development | Tarsus Pharmaceuticals, Inc. | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 5.20% 5.20%    
Drug Discovery & Development | Tarsus Pharmaceuticals, Inc. | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2],[9],[23] $ 2,100      
Total investments at fair value [9],[23] $ 2,280      
Acquisition Date [9] May 05, 2022 May 05, 2022    
Shares | shares [9],[23] 155,555 155,555    
Drug Discovery & Development | Iveric Bio, Inc. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2027-08 2027-08    
Investment Interest Rate Floor [7] 8.75% 8.75%    
Principal Amount [18],[23] $ 49,500      
Investment cost [2],[18],[23] 49,090      
Total investments at fair value [18],[23] $ 49,090      
Drug Discovery & Development | Iveric Bio, Inc. | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 4.25% 4.25%    
Drug Discovery & Development | Iveric Bio, Inc. | Senior Secured Debt | Cap rate        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 10.25% 10.25%    
Drug Discovery & Development | Iveric Bio, Inc. | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 4.00% 4.00%    
Drug Discovery & Development | AmplifyBio, LLC | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2027-01 2027-01    
Investment Interest Rate Floor [7] 9.50% 9.50%    
Principal Amount [25] $ 24,000      
Investment cost [2],[25] 23,663      
Total investments at fair value [25] $ 23,663      
Drug Discovery & Development | AmplifyBio, LLC | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 5.85% 5.85%    
Drug Discovery & Development | AmplifyBio, LLC | Senior Secured Debt | Cap rate        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 10.75% 10.75%    
Drug Discovery & Development | AmplifyBio, LLC | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 2.50% 2.50%    
Drug Discovery & Development | AmplifyBio, LLC | Warrant Investment | Class A Units        
Investment Holdings [Line Items]        
Investment cost [2],[25] $ 238      
Total investments at fair value [25] $ 256      
Acquisition Date [9] Dec. 27, 2022 Dec. 27, 2022    
Shares | shares [25] 69,239 69,239    
Drug Discovery & Development | HilleVax, Inc. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2027-05 2027-05    
Investment Interest Rate Floor [7] 4.55% 4.55%    
Investment Interest Rate Paid in Kind [7] 2.85% 2.85%    
Principal Amount [8],[11],[25] $ 12,072      
Investment cost [2],[8],[11],[25] 12,043      
Total investments at fair value [8],[11],[25] $ 11,333      
Drug Discovery & Development | HilleVax, Inc. | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 7.15% 7.15%    
Drug Discovery & Development | HilleVax, Inc. | Senior Secured Debt | Cap rate        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 6.05% 6.05%    
Drug Discovery & Development | HilleVax, Inc. | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 1.05% 1.05%    
Drug Discovery & Development | HilleVax, Inc. | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2],[9] $ 4,000      
Total investments at fair value [9] $ 3,937      
Acquisition Date [9] May 03, 2022 May 03, 2022    
Shares | shares [9] 235,295 235,295    
Drug Discovery & Development | Kura Oncology, Inc. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2027-11 2027-11    
Investment Interest Rate Floor [7] 8.65% 8.65%    
Principal Amount [8],[23],[25] $ 5,500      
Investment cost [2],[8],[23],[25] 5,448      
Total investments at fair value [8],[23],[25] $ 5,448      
Drug Discovery & Development | Kura Oncology, Inc. | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 15.13% 15.13%    
Drug Discovery & Development | Kura Oncology, Inc. | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 2.40% 2.40%    
Drug Discovery & Development | Kura Oncology, Inc. | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2],[9],[23],[25] $ 88      
Total investments at fair value [9],[23],[25] $ 59      
Acquisition Date [9] Nov. 02, 2022 Nov. 02, 2022    
Shares | shares [9],[23],[25] 14,342 14,342    
Drug Discovery & Development | Madrigal Pharmaceutical, Inc. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2026-05 2026-05    
Investment Interest Rate Floor [7] 7.45% 7.45%    
Principal Amount [8],[23] $ 34,000      
Investment cost [2],[8],[23] 33,945      
Total investments at fair value [8],[23] $ 33,987      
Drug Discovery & Development | Madrigal Pharmaceutical, Inc. | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 5.35% 5.35%    
Drug Discovery & Development | Madrigal Pharmaceutical, Inc. | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 3.95% 3.95%    
Drug Discovery & Development | Madrigal Pharmaceutical, Inc. | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2],[9],[23] $ 177      
Total investments at fair value [9],[23] $ 1,977      
Acquisition Date [9] May 09, 2022 May 09, 2022    
Shares | shares [9],[23] 10,131 10,131    
Drug Discovery & Development | Forbion Growth Opportunities Fund I C V | Investment Funds & Vehicles [Member]        
Investment Holdings [Line Items]        
Investment cost [2],[8],[23],[24] $ 2,699      
Total investments at fair value [8],[23],[24] $ 3,080      
Acquisition Date [9] Nov. 16, 2020 Nov. 16, 2020    
Drug Discovery & Development | Dynavax Technologies | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 550 [2],[9],[23]   550 [1],[4],[6]  
Total investments at fair value $ 213 [9],[23]   $ 281 [4],[6]  
Acquisition Date Jul. 22, 2015 [9] Jul. 22, 2015 [9] Jul. 22, 2015 [6] Jul. 22, 2015 [6]
Shares | shares 20,000 [9],[23] 20,000 [9],[23] 20,000 [4],[6] 20,000 [4],[6]
Drug Discovery & Development | Genocea Biosciences Inc | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost [1],[6]     $ 2,000  
Total investments at fair value [6]     $ 32  
Acquisition Date [6]     Nov. 20, 2014 Nov. 20, 2014
Shares | shares [6]     27,933 27,933
Drug Discovery & Development | Genocea Biosciences Inc | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost [1],[6]     $ 165  
Total investments at fair value [6]     $ 1  
Acquisition Date [6]     Apr. 24, 2018 Apr. 24, 2018
Shares | shares [6]     41,176 41,176
Drug Discovery & Development | NorthSea Therapeutics | Equity | Preferred Series C        
Investment Holdings [Line Items]        
Investment cost $ 2,000 [2],[23],[24]   $ 2,000 [1],[4],[5]  
Total investments at fair value $ 1,476 [23],[24]   $ 2,000 [4],[5]  
Acquisition Date Dec. 15, 2021 [9] Dec. 15, 2021 [9] Dec. 15, 2021 [6] Dec. 15, 2021 [6]
Shares | shares 983 [23],[24] 983 [23],[24] 983 [4],[5] 983 [4],[5]
Drug Discovery & Development | Sio Gene Therapies, Inc. | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 1,269 [2],[9]   $ 1,269 [1],[4],[6]  
Total investments at fair value $ 7 [9]   $ 21 [4],[6]  
Acquisition Date Feb. 02, 2017 [9] Feb. 02, 2017 [9] Feb. 02, 2017 [6] Feb. 02, 2017 [6]
Shares | shares 16,228 [9] 16,228 [9] 16,228 [4],[6] 16,228 [4],[6]
Drug Discovery & Development | Valo Health L L C | Equity        
Investment Holdings [Line Items]        
Investment cost [2] $ 4,000      
Total investments at fair value $ 3,075      
Shares | shares 680,410 680,410    
Drug Discovery & Development | Valo Health L L C | Equity | Preferred Series B        
Investment Holdings [Line Items]        
Investment cost $ 3,000 [2]   $ 3,000 [1]  
Total investments at fair value $ 2,063   $ 4,650  
Acquisition Date Dec. 11, 2020 [9] Dec. 11, 2020 [9] Dec. 11, 2020 [6] Dec. 11, 2020 [6]
Shares | shares 510,308 510,308 510,308 510,308
Drug Discovery & Development | Valo Health L L C | Equity | Preferred Series C        
Investment Holdings [Line Items]        
Investment cost [2] $ 1,000      
Total investments at fair value $ 1,012      
Acquisition Date [9] Oct. 31, 2022 Oct. 31, 2022    
Shares | shares 170,102 170,102    
Drug Discovery & Development | Paratek Pharmaceuticals, Inc. | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 2,744 [2],[9]   $ 2,744 [1],[6]  
Total investments at fair value $ 143 [9]   $ 343 [6]  
Acquisition Date Feb. 26, 2007 [9] Feb. 26, 2007 [9] Feb. 26, 2007 [6] Feb. 26, 2007 [6]
Shares | shares 76,362 [9] 76,362 [9] 76,362 [6] 76,362 [6]
Drug Discovery & Development | Paratek Pharmaceuticals, Inc. | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 520 [2],[9]   $ 546 [1],[6]  
Total investments at fair value $ 34 [9]   $ 427 [6]  
Acquisition Date Aug. 01, 2018 [9] Aug. 01, 2018 [9] Jun. 27, 2017 [6] Jun. 27, 2017 [6]
Shares | shares 426,866 [9] 426,866 [9] 432,240 [6] 432,240 [6]
Drug Discovery & Development | Rocket Pharmaceuticals, Ltd. | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 1,500 [2],[9]   $ 1,500 [1],[6]  
Total investments at fair value $ 18 [9]   $ 21 [6]  
Acquisition Date Aug. 22, 2007 [9] Aug. 22, 2007 [9] Aug. 22, 2007 [6] Aug. 22, 2007 [6]
Shares | shares 944 [9] 944 [9] 944 [6] 944 [6]
Drug Discovery & Development | Savara, Inc. | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 203 [2],[9]   $ 202 [1],[6]  
Total investments at fair value $ 17 [9]   $ 14 [6]  
Acquisition Date Aug. 11, 2015 [9] Aug. 11, 2015 [9] Aug. 11, 2015 [6] Aug. 11, 2015 [6]
Shares | shares 11,119 [9] 11,119 [9] 11,119 [6] 11,119 [6]
Drug Discovery & Development | Tricida, Inc. | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 863 [2],[9]   $ 863 [1],[6]  
Total investments at fair value $ 11 [9]   $ 658 [6]  
Acquisition Date Feb. 28, 2018 [9] Feb. 28, 2018 [9] Feb. 28, 2018 [6] Feb. 28, 2018 [6]
Shares | shares 68,816 [9] 68,816 [9] 68,816 [6] 68,816 [6]
Drug Discovery & Development | Tricida, Inc. | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 280 [2],[9]   $ 280 [1],[6]  
Total investments at fair value $ 1 [9]   $ 20 [6]  
Acquisition Date Mar. 27, 2019 [9] Mar. 27, 2019 [9] Mar. 27, 2019 [6] Mar. 27, 2019 [6]
Shares | shares 31,352 [9] 31,352 [9] 31,352 [6] 31,352 [6]
Drug Discovery & Development | Concert Pharmaceuticals, Inc. | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 1,367 [2],[9],[23]   $ 1,367 [1],[4],[6]  
Total investments at fair value $ 413 [9],[23]   $ 223 [4],[6]  
Acquisition Date Feb. 13, 2019 [9] Feb. 13, 2019 [9] Feb. 13, 2019 [6] Feb. 13, 2019 [6]
Shares | shares 70,796 [9],[23] 70,796 [9],[23] 70,796 [4],[6] 70,796 [4],[6]
Drug Discovery & Development | Concert Pharmaceuticals, Inc. | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost [1],[4],[6]     $ 178  
Total investments at fair value [4],[6]     $ 3  
Acquisition Date [6]     Jun. 08, 2017 Jun. 08, 2017
Shares | shares [4],[6]     61,273 61,273
Drug Discovery & Development | Gritstone Bio, Inc. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2027-07 2027-07    
Investment Interest Rate Floor [7] 7.15% 7.15%    
Investment Interest Rate Paid in Kind [7] 2.00% 2.00%    
Principal Amount [8],[11] $ 15,113      
Investment cost [2],[8],[11] 15,109      
Total investments at fair value [8],[11] $ 15,109      
Drug Discovery & Development | Gritstone Bio, Inc. | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 5.75% 5.75%    
Drug Discovery & Development | Gritstone Bio, Inc. | Senior Secured Debt | Cap rate        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 8.65% 8.65%    
Drug Discovery & Development | Gritstone Bio, Inc. | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [7] 3.15% 3.15%    
Drug Discovery & Development | Gritstone Bio, Inc. | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2],[9] $ 1,000      
Total investments at fair value [9] $ 1,527      
Acquisition Date [9] Oct. 26, 2022 Oct. 26, 2022    
Shares | shares [9] 442,477 442,477    
Drug Discovery & Development | Dare Biosciences, Inc. | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 1,000 [2],[9]   $ 1,000 [1],[6]  
Total investments at fair value $ 11 [9]   $ 27 [6]  
Acquisition Date Jan. 08, 2015 [9] Jan. 08, 2015 [9] Jan. 08, 2015 [6] Jan. 08, 2015 [6]
Shares | shares 13,550 [9] 13,550 [9] 13,550 [6] 13,550 [6]
Drug Discovery & Development | Applied Molecular Transport | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 42 [2],[9],[23]   $ 42 [1],[4],[6]  
Total investments at fair value $ 0 [9],[23]   $ 14 [4],[6]  
Acquisition Date Apr. 06, 2021 [9] Apr. 06, 2021 [9] Apr. 06, 2021 [6] Apr. 06, 2021 [6]
Shares | shares 1,000 [9],[23] 1,000 [9],[23] 1,000 [4],[6] 1,000 [4],[6]
Drug Discovery & Development | Avalo Therapeutics Inc P K Cerecor Inc | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 1,000 [2],[9]   $ 1,000 [1],[6]  
Total investments at fair value $ 50 [9]   $ 202 [6]  
Acquisition Date Aug. 19, 2014 [9] Aug. 19, 2014 [9] Aug. 19, 2014 [6] Aug. 19, 2014 [6]
Shares | shares 9,924 [9] 9,924 [9] 119,087 [6] 119,087 [6]
Drug Discovery & Development | Albireo Pharma, Inc. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date     2024-07 2024-07
Investment Interest Rate Floor [12]     9.15% 9.15%
Principal Amount [4],[15]     $ 10,000  
Investment cost [1],[4],[15]     10,229  
Total investments at fair value [4],[15]     $ 10,268  
Drug Discovery & Development | Albireo Pharma, Inc. | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [12]     6.95% 6.95%
Drug Discovery & Development | Albireo Pharma, Inc. | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [12]     5.90% 5.90%
Drug Discovery & Development | Albireo Pharma, Inc. | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 1,000 [2],[9],[23]   $ 1,000 [1],[4],[6]  
Total investments at fair value $ 540 [9],[23]   $ 582 [4],[6]  
Acquisition Date Sep. 14, 2020 [9] Sep. 14, 2020 [9] Sep. 14, 2020 [6] Sep. 14, 2020 [6]
Shares | shares 25,000 [9],[23] 25,000 [9],[23] 25,000 [4],[6] 25,000 [4],[6]
Drug Discovery & Development | Albireo Pharma, Inc. | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 61 [2],[9],[23]   $ 61 [1],[4],[6]  
Total investments at fair value $ 31 [9],[23]   $ 42 [4],[6]  
Acquisition Date Jun. 08, 2020 [9] Jun. 08, 2020 [9] Jun. 08, 2020 [6] Jun. 08, 2020 [6]
Shares | shares 5,311 [9],[23] 5,311 [9],[23] 5,311 [4],[6] 5,311 [4],[6]
Drug Discovery & Development | Aldeyra Therapeutics, Inc. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2024-10 2024-10 2023-10 2023-10
Investment Interest Rate Floor 8.60% [7] 8.60% [7] 8.60% [12] 8.60% [12]
Principal Amount $ 15,000 [13]   $ 15,000  
Investment cost 15,879 [2],[13]   15,639 [1]  
Total investments at fair value $ 15,974 [13]   $ 15,653  
Drug Discovery & Development | Aldeyra Therapeutics, Inc. | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor 8.90% [7] 8.90% [7] 6.95% [12] 6.95% [12]
Drug Discovery & Development | Aldeyra Therapeutics, Inc. | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate 3.10% [7] 3.10% [7] 3.10% [12] 3.10% [12]
Drug Discovery & Development | Applied Genetic Technologies Corporation | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date     2024-04 2024-04
Investment Interest Rate Floor [12]     9.75% 9.75%
Principal Amount     $ 20,000  
Investment cost [1]     20,416  
Total investments at fair value     $ 20,339  
Drug Discovery & Development | Applied Genetic Technologies Corporation | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [12]     6.95% 6.95%
Drug Discovery & Development | Applied Genetic Technologies Corporation | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [12]     6.50% 6.50%
Drug Discovery & Development | Aveo Pharmaceuticals, Inc. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2024-09 2024-09 2024-09 2024-09
Investment Interest Rate Floor 9.65% [7] 9.65% [7] 9.65% [12] 9.65% [12]
Principal Amount $ 40,000 [13],[25]   $ 40,000 [15],[31]  
Investment cost 41,644 [2],[13],[25]   40,842 [1],[15],[31]  
Total investments at fair value $ 43,183 [13],[25]   $ 40,776 [15],[31]  
Drug Discovery & Development | Aveo Pharmaceuticals, Inc. | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor 6.95% [7] 6.95% [7] 6.95% [12] 6.95% [12]
Drug Discovery & Development | Aveo Pharmaceuticals, Inc. | Senior Secured Debt | Cap rate        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 15.00% 15.00%    
Drug Discovery & Development | Aveo Pharmaceuticals, Inc. | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate 6.40% [7] 6.40% [7] 6.40% [12] 6.40% [12]
Drug Discovery & Development | Aveo Pharmaceuticals, Inc. | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 1,715 [2],[9]   $ 1,715 [1],[6]  
Total investments at fair value $ 2,843 [9]   $ 892 [6]  
Acquisition Date Jul. 31, 2011 [9] Jul. 31, 2011 [9] Jul. 31, 2011 [6] Jul. 31, 2011 [6]
Shares | shares 190,179 [9] 190,179 [9] 190,179 [6] 190,179 [6]
Drug Discovery & Development | Acacia Pharma Inc. | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 304 [2],[23],[24]   $ 305 [1],[4],[5],[6]  
Total investments at fair value $ 0 [23],[24]   $ 6 [4],[5],[6]  
Acquisition Date Jun. 29, 2018 [9] Jun. 29, 2018 [9] Jun. 29, 2018 [6] Jun. 29, 2018 [6]
Shares | shares 201,330 [23],[24] 201,330 [23],[24] 201,330 [4],[5],[6] 201,330 [4],[5],[6]
Drug Discovery & Development | ADMA Biologics, Inc. | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 166 [2],[9]   $ 295 [1],[6]  
Total investments at fair value $ 10 [9]   $ 1 [6]  
Acquisition Date Feb. 24, 2014 [9] Feb. 24, 2014 [9] Dec. 21, 2012 [6] Dec. 21, 2012 [6]
Shares | shares 58,000 [9] 58,000 [9] 89,750 [6] 89,750 [6]
Drug Discovery & Development | Axsome Therapeutics, Inc. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2026-10 2026-10 2026-10 2026-10
Investment Interest Rate Floor 8.95% [7] 8.95% [7] 8.95% [12] 8.95% [12]
Principal Amount $ 81,725 [8],[13],[18],[19],[23]   $ 50,000 [4],[32]  
Investment cost 81,631 [2],[8],[13],[18],[19],[23]   49,542 [1],[4],[32]  
Total investments at fair value $ 78,074 [8],[13],[18],[19],[23]   $ 48,859 [4],[32]  
Drug Discovery & Development | Axsome Therapeutics, Inc. | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor 5.31% [7] 5.31% [7] 5.82% [12] 5.82% [12]
Drug Discovery & Development | Axsome Therapeutics, Inc. | Senior Secured Debt | Cap rate        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 10.70% 10.70%    
Drug Discovery & Development | Axsome Therapeutics, Inc. | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate 5.70% [7] 5.70% [7] 5.70% [12] 5.70% [12]
Drug Discovery & Development | Axsome Therapeutics, Inc. | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost [2],[9],[19],[23] $ 4,165      
Total investments at fair value [9],[19],[23] $ 9,797      
Acquisition Date [9] May 09, 2022 May 09, 2022    
Shares | shares [9],[19],[23] 127,021 127,021    
Drug Discovery & Development | Axsome Therapeutics, Inc. | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 880 [2],[9],[18],[19],[23]   $ 681 [1],[4],[6]  
Total investments at fair value $ 1,590 [9],[18],[19],[23]   $ 142 [4],[6]  
Acquisition Date Sep. 25, 2020 [9] Sep. 25, 2020 [9] Sep. 25, 2020 [6] Sep. 25, 2020 [6]
Shares | shares 40,396 [9],[18],[19],[23] 40,396 [9],[18],[19],[23] 15,541 [4],[6] 15,541 [4],[6]
Drug Discovery & Development | Brickell Biotech, Inc. | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 119 [2],[9]   $ 119 [1],[6]  
Total investments at fair value $ 0 [9]   $ 0 [6]  
Acquisition Date Feb. 18, 2016 [9] Feb. 18, 2016 [9] Feb. 18, 2016 [6] Feb. 18, 2016 [6]
Shares | shares 200 [9] 200 [9] 9,005 [6] 9,005 [6]
Drug Discovery & Development | Bicycle Therapeutics PLC | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2025-07 2025-07 2024-10 2024-10
Investment Interest Rate Floor 8.05% [7] 8.05% [7] 8.85% [12] 8.85% [12]
Principal Amount $ 11,500 [13],[18],[23],[24]   $ 24,000 [3],[4],[5],[15],[32]  
Investment cost 11,757 [2],[13],[18],[23],[24]   24,271 [1],[3],[4],[5],[15],[32]  
Total investments at fair value $ 11,435 [13],[18],[23],[24]   $ 24,454 [3],[4],[5],[15],[32]  
Drug Discovery & Development | Bicycle Therapeutics PLC | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor 5.00% [7] 5.00% [7] 5.00% [12] 5.00% [12]
Drug Discovery & Development | Bicycle Therapeutics PLC | Senior Secured Debt | Cap rate        
Investment Holdings [Line Items]        
Interest Rate and Floor [7] 9.05% 9.05%    
Drug Discovery & Development | Bicycle Therapeutics PLC | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate 4.55% [7] 4.55% [7] 5.60% [12] 5.60% [12]
Drug Discovery & Development | Bicycle Therapeutics PLC | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 1,871 [2],[9],[23],[24]   $ 1,871 [1],[4],[5],[6]  
Total investments at fair value $ 2,904 [9],[23],[24]   $ 5,971 [4],[5],[6]  
Acquisition Date Oct. 05, 2020 [9] Oct. 05, 2020 [9] Oct. 05, 2020 [6] Oct. 05, 2020 [6]
Shares | shares 98,100 [9],[23],[24] 98,100 [9],[23],[24] 98,100 [4],[5],[6] 98,100 [4],[5],[6]
Drug Discovery & Development | BiomX, INC | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2025-09 2025-09 2025-09 2025-09
Investment Interest Rate Floor 8.95% [7] 8.95% [7] 8.95% [12] 8.95% [12]
Principal Amount $ 9,000 [13],[23],[24]   $ 9,000 [4],[5],[15]  
Investment cost 9,174 [2],[13],[23],[24]   8,980 [1],[4],[5],[15]  
Total investments at fair value $ 9,052 [13],[23],[24]   $ 8,980 [4],[5],[15]  
Drug Discovery & Development | BiomX, INC | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor 6.55% [7] 6.55% [7] 6.55% [12] 6.55% [12]
Drug Discovery & Development | BiomX, INC | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate 5.70% [7] 5.70% [7] 5.70% [12] 5.70% [12]
Drug Discovery & Development | BridgeBio Pharma, Inc. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2026-11 2026-11 2026-11 2026-11
Principal Amount $ 37,312 [11],[17],[18]   $ 38,000  
Investment Interest Rate Paid in Cash 9.00% [7] 9.00% [7] 9.00% [12] 9.00% [12]
Investment cost $ 37,039 [2],[11],[17],[18]   $ 37,462 [1]  
Total investments at fair value $ 33,344 [11],[17],[18]   $ 37,462  
Drug Discovery & Development | BridgeBio Pharma, Inc. | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor 2.00% [7] 2.00% [7] 2.00% [12] 2.00% [12]
Drug Discovery & Development | BridgeBio Pharma, Inc. | Equity | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 2,255 [2],[9]   $ 2,255 [1],[6]  
Total investments at fair value $ 1,763 [9]   $ 3,859 [6]  
Acquisition Date Jun. 21, 2018 [9] Jun. 21, 2018 [9] Jun. 21, 2018 [6] Jun. 21, 2018 [6]
Shares | shares 231,329 [9] 231,329 [9] 231,329 [6] 231,329 [6]
Drug Discovery & Development | Cellarity, Inc. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2026-06 2026-06 2026-06 2026-06
Investment Interest Rate Floor 8.95% [7] 8.95% [7] 8.95% [12] 8.95% [12]
Principal Amount $ 30,000 [17],[25]   $ 30,000 [31]  
Investment cost 29,841 [2],[17],[25]   29,422 [1],[31]  
Total investments at fair value $ 30,097 [17],[25]   $ 29,422 [31]  
Drug Discovery & Development | Cellarity, Inc. | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor 3.75% [7] 3.75% [7] 3.75% [12] 3.75% [12]
Drug Discovery & Development | Cellarity, Inc. | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate 5.70% [7] 5.70% [7] 5.70% [12] 5.70% [12]
Drug Discovery & Development | Cellarity, Inc. | Warrant Investment | Preferred Series B        
Investment Holdings [Line Items]        
Investment cost $ 287 [2],[25]   $ 287 [1],[31]  
Total investments at fair value $ 318 [25]   $ 287 [31]  
Acquisition Date Dec. 08, 2021 [9] Dec. 08, 2021 [9] Dec. 08, 2021 [6] Dec. 08, 2021 [6]
Shares | shares 100,000 [25] 100,000 [25] 100,000 [31] 100,000 [31]
Drug Discovery & Development | Center for Breakthrough Medicines Holdings, LLC [Member] | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date     2023-05 2023-05
Investment Interest Rate Floor [12]     8.75% 8.75%
Principal Amount     $ 5,000  
Investment cost [1]     5,005  
Total investments at fair value     $ 5,005  
Drug Discovery & Development | Center for Breakthrough Medicines Holdings, LLC [Member] | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor [12]     7.50% 7.50%
Drug Discovery & Development | Center for Breakthrough Medicines Holdings, LLC [Member] | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate [12]     5.50% 5.50%
Drug Discovery & Development | Century Therapeutics, Inc. | Senior Secured Debt        
Investment Holdings [Line Items]        
Maturity Date 2024-04 2024-04 2024-04 2024-04
Investment Interest Rate Floor 9.55% [7] 9.55% [7] 9.55% [12] 9.55% [12]
Principal Amount $ 10,000 [13]   $ 10,000 [15]  
Investment cost 10,235 [2],[13]   10,075 [1],[15]  
Total investments at fair value $ 10,292 [13]   $ 10,361 [15]  
Drug Discovery & Development | Century Therapeutics, Inc. | Senior Secured Debt | Exit Fee Interest Income        
Investment Holdings [Line Items]        
Interest Rate and Floor 3.95% [7] 3.95% [7] 3.95% [12] 3.95% [12]
Drug Discovery & Development | Century Therapeutics, Inc. | Senior Secured Debt | Prime Rate        
Investment Holdings [Line Items]        
Investment Basis Spread Variable Rate 6.30% [7] 6.30% [7] 6.30% [12] 6.30% [12]
Drug Discovery & Development | Century Therapeutics, Inc. | Warrant Investment | Common Stock        
Investment Holdings [Line Items]        
Investment cost $ 37 [2],[9]   $ 37 [1],[6]  
Total investments at fair value $ 3 [9]   $ 64 [6]  
Acquisition Date Sep. 14, 2020 [9] Sep. 14, 2020 [9] Sep. 14, 2020 [6] Sep. 14, 2020 [6]
Shares | shares 16,112 [9] 16,112 [9] 16,112 [6] 16,112 [6]
Drug Discovery & Development | Chemocentryx Inc One | Senior Secured Debt